Global Blood Cancer Drugs Market - 2020-2027
|出版日期||內容資訊||英文 180 Pages
|血癌治療藥的全球市場(2020年∼2027年) Global Blood Cancer Drugs Market - 2020-2027|
|出版日期: 2021年05月27日||內容資訊: 英文 180 Pages||
The global blood cancer drugs market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Blood cancer is a serious and life-threatening cancer that affects either production or function of blood cells such as bone marrow and tissues which results in dysfunctional of lymphatic system. The characteristics sign and symptoms of blood cancer is severe abdominal pain, bone and joints pain, gradually weight loss, dark spots, excessive or easy bruising and weakness. Blood cancers occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells.
Globally, blood cancer are the fifth most common cancer and is the second most leading cause of cancer deaths. The global blood cancer drugs market is projected to register a moderate growth rate in the market and which is anticipated due to, high demand of diseases specific treatment, rise in adoption of newer technologies, presence of refined healthcare infrastructure and increased patient awareness level as well as high prevalence of blood cancer.
The blood cancer drugs market growth is driven by increase awareness amongst healthcare professionals and patients about the possibility of early diagnosis of cancer, increase in government funding for research is anticipated to accelerate the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from U.S. congress to support cancer-related activities, are expected to drive the market growth in the forecast period.
The growing death incidences and increasing prevalence of blood cancer cases across the globe
The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death.
According to Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukaemia, and 275,047 cases myeloma.
Furthermore, the report estimated, in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000. In 2019, more than 387,000 people are living with leukaemia in the United States and an estimated 68,000 deaths will result from blood cancer.
According to national cancer institute, the estimated deaths due to blood cancer are expected to be around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drugs market.
Formulations of new regulatory approvals for new drugs for blood cancer are expected to boost the growth
The formulations of new regulatory approvals for new drugs for blood cancer are expected to boost the growth of market. For instance, in 2015, Pfizer announced that inotuzumab (antibody-drug conjugate) received a breakthrough therapy designation from U.S. FDA for acute lymphoblastic leukemia.
Increasing awareness amongst healthcare professionals and patients about the possibility of early diagnosis of cancer and increase in government funding for research is anticipated to accelerate the market growth during the forecast period. Institutes like National Cancer Institute (NCI) receive funds from U.S. congress to support cancer-related activities.
High drug approval costs hinders the growth of the blood cancer drugs market
However, Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments. According to Tufts Centre for the Study of Drug Development, the cost of bringing a new drug from its conception to shelves is about $2.7 billion. Thus indicating that the high drug approval costs hinders the growth of the blood cancer drugs market.
COVID-19 Impact Analysis
Due to the outbreak of the COVID-19, the market observed a significant setback in terms of growth. As the COVID-19 cases were rising, the healthcare system had shifted its focus in curbing the disease thereby resulting in the delay of diagnosis and treatment of other chronic conditions like blood cancer.
Thus, a negative impact is expected on the blood cancer drugs market due to the pandemic scenario. However, in the coming years, a significant rise is expected in the diagnostic procedures related to cancer.
By type , the blood cancer drugs market is classified into leukemia, non-hodgkin lymphoma, hodgkin lymphoma, and myeloma.
Leukemia segment is expected to grow at the fastest CAGR during the forecast period (2020-2027)
Leukemia is a blood cancer that originates in the blood and bone marrow. It occurs when the body creates too many abnormal white blood cells and interferes with the bone marrow's ability to make red blood cells and platelets.
It causes the body to make white blood cells that grow out of control and live longer than they're supposed to. And unlike normal white blood cells, they don't help body fight infection. Over time, the leukemia cells crowd out or suppress the development of normal cells. The rate at which leukemia progresses and how the cells replace the normal blood and marrow cells are different with each type of leukemia. After diagnosis and treatment, many people with leukemia live many good, quality years. The presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are reported to be some of the highest revenue-generating leukemia drugs are driving the market growth.
Non-Hodgkin lymphoma has the second largest share in the segment. Non-Hodgkin lymphoma (also known as non-Hodgkin's lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in white blood cells called lymphocytes, which are part of the body's immune system.
Advances in diagnosis and treatment of non-Hodgkin's lymphoma have helped improve the prognosis for people with this disease. In most cases, people diagnosed with non-Hodgkin's lymphoma don't have any obvious risk factors. And many people who have risk factors for the disease never develop it.
On the basis of drugs type, the the blood cancer drugs market is classified into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Others.
The Rituaxan/Mabthera (Rituximab) drugs segment are expected to dominate the blood cancer drugs market during the forecast period
The Mabthera was the first therapeutic monoclonal antibody to target cells that have the CD20 marker on their surface. These cells are central to many blood cancers, including common forms of lymphoma and leukaemia. Mabthera attacks these cells both directly and together with the body's immune system.
In the United States, Europe and in other countries, Mabthera is approved for the treatment of adults with the following blood cancers, previously untreated and relapsed/refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Mabthera is also approved for the treatment of adults in auto-immune diseases, severe active rheumatoid arthritis, pemphigus vulgaris and severe active granulomatosis with polyangiitis and microscopic polyangiitis (GPA/MPA).
Gleevac/Glivec (Imatinib) has also second largest share in the market. NCI-supported research led to a series of discoveries that resulted in the development of imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with a type of blood cancer called chronic myelogenous leukemia. These discoveries also helped establish a new group of drugs (known as targeted therapy) that has changed the field of cancer research.
North America region holds the largest market share global blood cancer drugs market
North America region is dominating the global blood cancer drugs market accounted for the largest market share in 2019, owing to the presence of key players in the region, availability of sophisticated healthcare infrastructure, and increasing awareness of blood cancer. Besides, favorable government initiatives and increase in number of research collaborations are some of the drivers expected to accelerate the market growth. In 2019, Eli Lilly, a US-based Pharmaceutical company, acquired Loxo Oncology, a cancer-focused biotechnology company for $8 billion. This acquisition of Loxo Oncology provides Lilly with a promising pipeline of investigational medicines such as oral RET inhibitor, oral BTK inhibitor and others. The deal would enable Lilly to attain strong patent on Loxo's genetically based approach to treat cancer. Loxo Oncology, is a biopharmaceutical company, developing and selling medicines for patients with genetically defined cancers.
On the other hand, Asia-Pacific is expected to exhibit the fastest growth rate over the forecast period owing to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and availability of effective treatment in emerging countries, such as China and India.
The Blood Cancer Drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly. Bristol-Myers Squibb Company, Gilead Sciences, Inc., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, UCB SA among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the blood cancer drugs market globally.
Overview: Amgen Inc. is an independent biotechnology medicines company that discovers, develops, manufactures and markets medicines for grievous illnesses. The Company focuses solely on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis, Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.
Product Portfolio: The Company's portfolio comprised of inflammation, oncology/hematology, bone health, cardiovascular disease, and nephrology and neuroscience areas.
Key Development: In January 2016, Amgen and Merck announced a cancer immunotherapy collaboration to support a Phase 1b/3 study investigating BLINCYTO (blinatumomab) in combination with KEYTRUDA (pembrolizumab) in patients with diffuse large B-cell lymphoma (DLBCL), which is the most common type of non-Hodgkin lymphoma (NHL). BLINCYTO is Amgen's CD19 bispecific T cell engager (BiTE), and KEYTRUDA is Merck's anti-PD-1 therapy. The study is an open-label, multicenter, randomized trial to evaluate safety and efficacy in patients with DLBCL.
The global blood cancer drugs market report would provide an access to an approx. 70 market data table, 68 figures and 200 pages.
LIST NOT EXHAUSTIVE